Citations

Clear

6273 citation(s) found for "To, Andrew".

Cost effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects ( EMERGE )—A randomised placebo‐controlled clinical trial
Gillespie, Paddy , Mahon, R , Newman, C. , Alvarez‐Iglesias, Alberto , Smyth, Andrew , O’Shea, Paula , Egan, Aoife M. , O’Donnell, Martin , Dunne, Fidelma , Newman, Christine , Egan, A M , O'Shea, Paula M , Gillespie, Paddy , Dunne, Fidelma P , Ferguson, John P. , Devane, Declan

Mayo Clinic

Diabetic Medicine | April 4, 2025 | Volume: 42 | Issue: 6 | Pages: No page available

10.1111/dme.70036 | PMID 40173275 Get It

Abstract Aims To investigate the cost‐effectiveness of early initiation of metformin and usual care for gestational diabetes mellitus (GDM). Methods Economic evaluation from a healthcare perspective, based on the EMERGE randomised controlled trial. In total, 535 women with GDM were randomised to placebo in addition to usual care or metformin in addition to usual care. Economic outcomes included incremental healthcare costs and quality adjusted life years ( QALYs ) and expected cost‐effectiveness at cost‐effectiveness threshold values of €20,000, €45,000 and €100,000 per QALY gained. Uncertainty was explored using parametric, non‐parametric, deterministic and probabilistic methods and heterogeneity using subgroup analysis. Results On average, relative to the placebo arm, the early metformin arm was associated with non‐statistically significant mean increases of €193.07 (95% CI : −€789.88, €1176.01; p = 0.700) and 0.002 QALYs (95% CI : −0.009, 0.013; p = 0.771). In terms of expected cost‐effectiveness at threshold values of €20,000, €45,000 and €100,000 per QALY gained, the probability of the early metformin arm being more cost‐effective was estimated at 0.423, 0.452 and 0.524. Exploratory subgroup analyses provided more favourable but not definitive evidence in favour of the early metformin arm for cohorts with previous GDM and previous caesarean section. Conclusions We do not find definitive evidence that early initiation of metformin in addition to usual care for GDM was more cost‐effective than usual care alone. The clinical and economic evidence may be considered equivocal, but worthy of further examination.
Physiology of Continuous‐Flow Left Ventricular Assist Device Therapy
Rosenbaum, Andrew , Antaki, James F. , Behfar, Atta, Villavicencio, Mauricio A. , Stulak, John M., Kushwaha, Sudhir S. , Behfar, Atta

Mayo Clinic

Comprehensive Physiology | April 3, 2025 | Volume: 12 | Issue: 1 | Pages: 2731-2767

10.1002/j.2040-4603.2022.tb00201.x Get It

Abstract The expanding use of continuous‐flow left ventricular assist devices (CF‐LVADs) for end‐stage heart failure warrants familiarity with the physiologic interaction of the device with the native circulation. Contemporary devices utilize predominantly centrifugal flow and, to a lesser extent, axial flow rotors that vary with respect to their intrinsic flow characteristics. Flow can be manipulated with adjustments to preload and afterload as in the native heart, and ascertainment of the predicted effects is provided by differential pressure‐flow ( H ‐ Q ) curves or loops. Valvular heart disease, especially aortic regurgitation, may significantly affect adequacy of mechanical support. In contrast, atrioventricular and ventriculoventricular timing is of less certain significance. Although beneficial effects of device therapy are typically seen due to enhanced distal perfusion, unloading of the left ventricle and atrium, and amelioration of secondary pulmonary hypertension, negative effects of CF‐LVAD therapy on right ventricular filling and function, through right‐sided loading and septal interaction, can make optimization challenging. Additionally, a lack of pulsatile energy provided by CF‐LVAD therapy has physiologic consequences for end‐organ function and may be responsible for a series of adverse effects. Rheological effects of intravascular pumps, especially shear stress exposure, result in platelet activation and hemolysis, which may result in both thrombotic and hemorrhagic consequences. Development of novel solutions for untoward device‐circulatory interactions will facilitate hemodynamic support while mitigating adverse events. © 2021 American Physiological Society. Compr Physiol 12:1‐37, 2021.
Reply to Martin-Loeches and Rodriguez: Clinical Guidelines: Asking the Right Questions to Guide Fungal Infection Management
Epelbaum, Oleg , Pennington, Kelly M. , Hage, Chadi A. , Marinelli, Tina , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 2, 2025 | Volume: 211 | Issue: 6 | Pages: 1097-1098

10.1164/rccm.202501-0152le | PMID 40173454 Get It

The diagnostic role of pharmacological provocation testing in cardiac electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, t
Behr, Elijah R. , Winkel, Bo Gregers , Ensam, Bode , Alfie, Alberto , Arbelo, Elena , Berry, Colin , Conte, Giulio , Crotti, Lia , Corcia, M. Cecilia Gonzalez , Kaski, Juan Carlos , Schulze‐Bahr, Eric , Wilde, Arthur A.M. , Tfelt‐Hansen, Jacob , Wolpert, Christian, Cuesta, Alejandro, Damman, Peter, Dobrev, Dobromir, Drago, Fabrizio, Haugaa, Kristina, Krahn, Andrew, Krause, Ulrich, Lambiase, Pier D, Napolitano, Carlo, Odening, Katja E, Shimizu, Wataru, Veltmann, Christian, Lambiase, Pier D. , Odening, Katja E. , Cerrone, Marina , Conte, Giulio , Crotti, Lia , Kaski, Juan Carlos , Nademanee, Koonlawee , Postema, Pieter G , Priori, Silvia , Probst, Vincent , Sarquella-Brugada, Georgia , Schulze-Bahr, Eric , Tadros, Rafik , Wilde, Arthur A M , Tfelt-Hansen, Jacob , Behr, Elijah Raphael , Lambiase, Pier D , Odening, Katja E , Arbelo, Elena , Berry, Colin , Cerrone, Marina , Nademanee, Koonlawee , Postema, Pieter G. , Priori, Silvia G. , Tadros, Rafik , Wolpert, Christian, Cuesta, Alejandro, Damman, Peter, Dobrev, Dobromir, Drago, Fabrizio, Haugaa, Kristina, Krahn, Andrew, Krause, Ulrich, Napolitano, Carlo, Shimizu, Wataru, Veltmann, Christian

Mayo Clinic

Europace | April 1, 2025 | Volume: 27 | Issue: 4 | Pages: No page available

10.1093/europace/euaf067 | PMID 40165484 Get It

Abstract The pharmacological provocation test is a pivotal tool in cardiac electrophysiology for the diagnosis of potential causes of sudden cardiac death, sudden cardiac arrest (SCA), arrhythmias, symptoms, or ECG abnormalities. The 2022 European Society of Cardiology Guidelines for the Treatment of Ventricular Arrhythmias and Prevention of Sudden Cardiac Death offered guidance on provocation testing but did not describe the indications and requirements in depth. This clinical consensus statement, led by the European Heart Rhythm Association and approved by major international stakeholders, aims to advise the general cardiologist and the arrhythmia expert who to test and when, where, and how to do it. The statement focuses on current practice for the diagnosis of subclinical arrhythmia syndromes and the causes of SCA, building upon the recommendations of the Guidelines. We address the sodium channel blocker provocation test for patients suspected of Brugada syndrome as well as the use of epinephrine, isoproterenol, adenosine, ergonovine, and acetylcholine.
Reliability and Validity of Measuring Shoulder Internal and External Rotation Strength in Volleyball Specific Positions
Loepfe, John G., Nagelli, Christopher V. , Cherny, Chad E., Johnson, Andrew , Larson, Dirk R. , Johnson, Andrew J, Tagliero, Adam J. , Johnson, Andrew J., Johnson, Andrew

Mayo Clinic

International Journal of Sports Physical Therapy | March 31, 2025 | Volume: 20 | Issue: 4 | Pages: No page available

10.26603/001c.132170 | PMID 40182905 Get It

Background Overhead athletes are susceptible to shoulder injuries, among which rotator cuff injuries are common and often directly associated with muscle weakness. Therefore, valid and reliable measures of rotator cuff strength at sport specific positions may be a vital part of sports physical therapy practice. Purpose: The current study aimed to determine the inter- and intra-tester reliability of measuring shoulder internal rotation (IR) and external rotation (ER) strength at a novel testing position, 130° of abduction and compared to the 90°/90° position. A secondary aim was to assess concurrent validity between measurements taken with the Humac® Norm™ Isokinetic Dynamometer (IKD) and Microfet® 2 hand-held dynamometer (HHD). Study Design Inter-Rater and Intra-Rater Reliability and Criterion Validity Methods Twenty-five (n=25) healthy participants were recruited for this study. Exclusion criteria included prior shoulder surgery, shoulder injury within the last three months, and contraindications to exercise according to ACSM guidelines. Participants performed maximal isometric shoulder external and internal rotation strength testing at both 90° and 130° of shoulder abduction. On the first day, participants were tested on the IKD at both positions, followed by each tester using the HHD. Participants returned 7-14 days later for repeat testing using the HHD only. ICC values were calculated for each rater, instrument, and testing position. Bland-Altman plots were created to establish limits of agreement. Minimal detectable change values were calculated. Results Inter- and intra-rater reliability for testing isometric strength using a hand-held dynamometer was good to excellent for both shoulder positions with ICC values consistently above 0.8. Concurrent validity between the HHD and IKD was poor to moderate with ICC values ranging from 0.1-0.4. However, Bland-Altman plots demonstrated that the difference in strength measures was within the limits of agreement. Conclusion Shoulder IR and ER strength testing at 130° of abduction shows strong inter-rater and intra-rater reliability for measurement in sport specific positions. Level of Evidence Level 3
Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial
Desai, Milind Y. , Owens, Anjali , Saberi, Sara , Wang, Andrew , Wolski, Kathy, Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Zenker, Mark, Geske, Jeffrey B. , Naidu, Srihari S. , Lampl, Kathy, Nissen, Steven E. , Investigators, for the VALOR-HCM, Wolski, Kathy , Cremer, Paul C , Tower-Rader, Albree , Sherrid, Mark , Geske, Jeffrey B , Fermin, David , Naidu, Srihari S , Nissen, Steven E , Saberi, Sara , Wang, Andrew , Zenker, Mark, Sherrid, Mark V. , Fermin, David , Investigators, for the VALOR-HCM

Mayo Clinic

Circulation: Genomic and Precision Medicine | March 31, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circgen.125.005100 | PMID 40163785 Get It

A 23‐year‐old woman with a headache and imbalance
Marcelis, Lukas , Folpe, Andrew, Gupta, Sounak , Zepeda‐Mendoza, Cinthya , Zepeda-Mendoza, Cinthya J

Mayo Clinic

Brain Pathology | March 30, 2025 | Volume: 35 | Issue: 5 | Pages: No page available

10.1111/bpa.70008 | PMID 40159593 Get It

Deep learning for echocardiographic assessment and risk stratification of aortic, mitral, and tricuspid regurgitation: the DELINEATE-regurgitation study
Long, Aaron S. , Finer, Joshua , Hartzel, Dustin N. , Jing, Linyuan, Ruhl, Jeffrey , vanMaanen, David P., Elnabawi, Youssef , Metser, Gil , Duffy, Eamon , Mawson, Thomas, Tat, Emily , Kumaraiah, Deepa, Devereux, Richard B., Homma, Shunichi, Leon, Martin B. , Hahn, Rebecca T , Poterucha, Timothy J. , Ruhl, Jeffrey , Hahn, Rebecca T , Elias, Pierre , Poterucha, Timothy Joseph , Long, Aaron, Hartman, Heidi S. , Jing, Linyuan , Kelsey, Chris R. , Rocha, Daniel , Haggerty, Christopher M. , Maurer, Matthew J. , Einstein, Andrew Jeffrey , Beecy, Ashley , Devereux, Richard B.

Mayo Clinic

European Heart Journal | March 29, 2025 | Volume: 46 | Issue: 28 | Pages: 2780-2791

10.1093/eurheartj/ehaf248 | PMID 40156921 Get It

Abstract Background and Aims Classification and risk stratification in aortic (AR), mitral (MR), and tricuspid regurgitation (TR) remains a significant clinical challenge. This study aimed to develop an artificial intelligence (AI) system to assess valvular regurgitation and stratify MR-progression risk. Methods Using transthoracic echocardiograms (TTEs) at two sites (internal development/test, external test), the DELINEATE-Regurgitation system was developed to classify AR, MR, and TR severity using colour Doppler videos. Methods of summating video-level classifications into study-level predictions were tested, comparing single-view with multiview approaches integrating predictions across multiple videos. Model agreement with cardiologists was assessed by weighted kappa. A separate AI system (DELINEATE-MR-Progression) analysing colour Doppler videos was developed to predict which patients with mild, mild–moderate, and moderate MR were most likely to progress to moderate–severe or severe MR with analysis by Kaplan–Meier and Cox proportional hazards models. Results A total of 71 660 TTEs with 1 203 980 colour Doppler videos were included. The weighted kappa in internal/external test sets for regurgitation classification was 0.81/0.76 for AR, 0.76/0.72 for MR, and 0.73/0.64 for TR using a multiview approach taking all colour Doppler videos in a study, demonstrating substantial agreement with cardiologist interpretation with superiority of multiview over single view approaches. In the progression analysis, the AI score stratified MR-progression risk even when controlled for clinical factors known to be associated with MR progression [internal test set hazard ratio 4.1 (95% confidence interval 2.5–6.6)]. Conclusions An AI system can accurately classify AR, MR, and TR and predict MR progression beyond currently known risk factors.
Letter: Enhancing the Diagnostic Performance of the Oral Cholate Challenge Test: Implications for Avoidance of Potentially Unnecessary Endoscopy
Hassanein, Tarek , Keaveny, Andrew P. , Mantry, Parvez , Shiffman, Mitchell, Leise, Michael D. , Qureshi, Kamran , Smith, Alastair D., Imperial, Joanne C. , Everson, Gregory T. , Investigators, the SHUNT‐V, Leise, Michael, McRae, Michael P , Everson, Gregory T , Keaveny, Andrew P , McRae, Michael P. , Investigators, the SHUNT‐V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 29, 2025 | Volume: 61 | Issue: 11 | Pages: 1832-1833

10.1111/apt.70116 | PMID 40156280 Get It

Practical Anemia Bundle and Hemoglobin Recovery in Critical Illness
Hanson, Andrew C. , Fortune, Emma , Flaby, Gerald W., Schulte, Phillip J. , Hazelton, Valerie M., Beam, William B. , Anderson, Brenda, Karon, Brad S. , Kor, Daryl J. , Johnson, Matthew L. , Beam, W Brian, Charnin, Jonathan E. , Anderson, Brenda K, Karon, Brad, Warner, Matthew A. , Go, Ronald S. , Cheville, Andrea , Gajic, Ognjen

Mayo Clinic

JAMA Network Open | March 28, 2025 | Volume: 8 | Issue: 3 | Pages: e252353

10.1001/jamanetworkopen.2025.2353 | PMID 40152861 Get It

Importance Anemia is a common complication of surgery and acute illness that is associated with adverse clinical outcomes. The role of anemia prevention and treatment strategies in this setting remains unclear. Objective To evaluate the effect of a multifaceted anemia management bundle vs standard care on posthospitalization hemoglobin recovery and multidimensional functional outcomes in survivors of acute illness. Design, Setting, and Participants This parallel group randomized clinical trial, known as the Practical Anemia Bundle for Sustained Blood Recovery, was conducted at postsurgical and medical intensive care units at a large US medical center. Critically ill patients (aged ≥18 years) with moderate to severe anemia (hemoglobin concentration <10 g/dL) were enrolled between March 2022 and November 2023. Participants were randomly assigned 1:1 to the intervention or standard care group. Intention-to-treat analyses were performed between July 2024 and January 2025. Intervention The intervention bundle was delivered throughout the duration of hospitalization and included optimized phlebotomy practices, clinical decision support, and pharmacological anemia treatment with intravenous iron. Main Outcomes and Measures The primary outcome was the mean difference in hemoglobin concentration at 1 month after hospital discharge. Results A total of 100 patients (median [IQR] age, 68 [61-72] years; 57 men [57.0%]; 65 [65.0%] with postsurgical admission to the intensive care unit) were enrolled during acute illness. Forty-nine patients (49.0%) were assigned to receive the intervention, and 51 (51.0%) were assigned to receive standard care. Hemoglobin concentration at 1 month after discharge was greater in patients receiving the intervention vs standard care (median [IQR], 12.2 [11.8-13.0] g/dL vs 11.5 [10.2-12.6] g/dL; adjusted mean difference, 0.69 [95% CI, 0.13-1.20] g/dL; P = .02). Conclusions and Relevance This randomized clinical trial found that a multifaceted anemia prevention and treatment bundle was feasible, was well tolerated, and improved posthospitalization hemoglobin concentrations up to 3 months in critically ill adults. These findings can inform the design of future trials. Trial Registration ClinicalTrials.gov Identifier: NCT05167734